PI-88
information and resources from the National Cancer Institute
PI-88
A sulfated oligosaccharide. PI-88 inhibits heparanase activity and heparan sulfate binding to fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), resulting in decreased tumor proliferation, inhibition of angiogenesis, and inhibition of metastasis. PI-88
A sulfated oligosaccharide. PI-88 inhibits heparanase activity and heparan sulfate binding to fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), resulting in decreased tumor proliferation, inhibition of angiogenesis, and inhibition of metastasis.
|
|
|
|
news articles
10 Medical Breakthroughs to Watch for in the Next 10 Years 01 Apr 2006
International News Service, Australian researchers recently announced a drug called PI-88 that showed early success in preventing tumor growth by cutting off its blood supply. ...
Progen meets with FDA to progress PI-88 clinical development Mar 27, 2006
PharmaLive.com (press release), Industries (ASX: PGL, NASDAQ: PGLAF) is scheduled to meet with the FDA on 5 April to discuss the design of current clinical trials with PI-88 (the company's ...
Progen Half Yearly Financial Results Mar 15, 2006
PharmaLive.com (press release), 12.5% reduction in net R&D spend to $1.4M as a result of the completion of the single agent PI-88 melanoma trial, and co-funding arrangement with Medigen ...
Progen Industries Limited: AGM MD's Address Nov 18, 2005
PharmaLive.com (press release), ...recognized clinical development program with capabilities in clinical trial management to US FDA standards and internal GMP supply of PI-88 and PI-166 for ...
|
|
